Tags

Type your tag names separated by a space and hit enter

Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
Vaccine. 2022 Jun 23; 40(29):3963-3974.V

Abstract

BACKGROUND

Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010-11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet).

METHODS

We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012-2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose.

RESULTS

The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0-88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8-96.1) < 12 months to 85.1% (72.0-92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7-94.7) against fatal PCV13 IPD, 64.5% (43.7-77.6), 83.2% (73.7-89.3) and 85.1% (67.6-93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3-94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4-92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2-96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and -14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively.

CONCLUSIONS

PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.

Authors+Show Affiliations

Epiconcept, Paris, France.National Institute of Public Health, Prague, Czech Republic.Statens Serum Institut, Copenhagen, Denmark.Public Health England, London, United Kingdom.National Institute for Health and Welfare, Helsinki, Finland.ACTIV, Créteil, France.Health Protection Surveillance Centre Dublin, Ireland.National Institute for Public Health and the Environment, Bilthoven, the Netherlands.Norwegian Institute of Public Health, Oslo, Norway.Health Agency of Catalunya, Barcelona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain.General Directorate of Public Health Madrid, Spain.Public Health Institute of Navarra - IdiSNA, Pamplona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain.Public Health Scotland, Glasgow, Scotland, UK.National Institute of Public Health, Prague, Czech Republic.Statens Serum Institut, Copenhagen, Denmark.Public Health England, London, United Kingdom.National Institute for Health and Welfare, Helsinki, Finland; Tampere University, Tampere, Finland.Santé publique France, the National Public Health Institute, Saint-Maurice, France.Temple Street Children's University Hospital, Irish Pneumococcal Reference Laboratory, Dublin, Ireland.Academic Medical Centre, National Reference Laboratory for Bacterial Meningitis, Amsterdam, the Netherlands.Norwegian Institute of Public Health, Oslo, Norway.Hospital Sant Joan de Déu, and International University of Catalunya, Barcelona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain.General Directorate of Public Health Madrid, Spain.Public Health Institute of Navarra - IdiSNA, Pamplona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain.Bacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, Glasgow Royal Infirmary & MVLS, University of Glasgow, Glasgow, Scotland, UK.European Centre for Disease Prevention and Control, Stockholm, Sweden.European Centre for Disease Prevention and Control, Stockholm, Sweden.Epiconcept, Paris, France; Antwerp university, Antwerp, Belgium. Electronic address: ghanquet@skynet.be.No affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Observational Study

Language

eng

PubMed ID

35637067

Citation

Savulescu, Camelia, et al. "Effectiveness of 10 and 13-valent Pneumococcal Conjugate Vaccines Against Invasive Pneumococcal Disease in European Children: SpIDnet Observational Multicentre Study." Vaccine, vol. 40, no. 29, 2022, pp. 3963-3974.
Savulescu C, Krizova P, Valentiner-Branth P, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022;40(29):3963-3974.
Savulescu, C., Krizova, P., Valentiner-Branth, P., Ladhani, S., Rinta-Kokko, H., Levy, C., Mereckiene, J., Knol, M., Winje, B. A., Ciruela, P., de Miguel, S., Guevara, M., MacDonald, L., Kozakova, J., Slotved, H. C., Fry, N. K., Pekka Nuorti, J., Danis, K., Corcoran, M., ... Hanquet, G. (2022). Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine, 40(29), 3963-3974. https://doi.org/10.1016/j.vaccine.2022.05.011
Savulescu C, et al. Effectiveness of 10 and 13-valent Pneumococcal Conjugate Vaccines Against Invasive Pneumococcal Disease in European Children: SpIDnet Observational Multicentre Study. Vaccine. 2022 Jun 23;40(29):3963-3974. PubMed PMID: 35637067.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. AU - Savulescu,Camelia, AU - Krizova,Pavla, AU - Valentiner-Branth,Palle, AU - Ladhani,Shamez, AU - Rinta-Kokko,Hanna, AU - Levy,Corinne, AU - Mereckiene,Jolita, AU - Knol,Mirjam, AU - Winje,Brita A, AU - Ciruela,Pilar, AU - de Miguel,Sara, AU - Guevara,Marcela, AU - MacDonald,Laura, AU - Kozakova,Jana, AU - Slotved,Hans-Christian, AU - Fry,Norman K, AU - Pekka Nuorti,J, AU - Danis,Kostas, AU - Corcoran,Mary, AU - van der Ende,Arie, AU - Vestrheim,Didrik F, AU - Munoz-Almagro,Carmen, AU - Sanz,Juan-Carlos, AU - Castilla,Jesus, AU - Smith,Andrew, AU - Colzani,Edoardo, AU - Pastore Celentano,Lucia, AU - Hanquet,Germaine, AU - ,, Y1 - 2022/05/28/ PY - 2021/11/03/received PY - 2022/04/19/revised PY - 2022/05/04/accepted PY - 2022/6/1/pubmed PY - 2022/6/1/medline PY - 2022/5/31/entrez KW - 10-valent pneumococcal vaccine KW - 13-valent pneumococcal vaccine KW - Invasive pneumococcal disease KW - Pneumococcal Infections KW - Serotype KW - Streptococcus pneumoniae SP - 3963 EP - 3974 JF - Vaccine JO - Vaccine VL - 40 IS - 29 N2 - BACKGROUND: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010-11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). METHODS: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012-2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. RESULTS: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0-88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8-96.1) < 12 months to 85.1% (72.0-92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7-94.7) against fatal PCV13 IPD, 64.5% (43.7-77.6), 83.2% (73.7-89.3) and 85.1% (67.6-93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3-94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4-92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2-96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and -14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. CONCLUSIONS: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/35637067/Effectiveness_of_10_and_13_valent_pneumococcal_conjugate_vaccines_against_invasive_pneumococcal_disease_in_European_children:_SpIDnet_observational_multicentre_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(22)00581-3 DB - PRIME DP - Unbound Medicine ER -